Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

BackgroundWhether the clinical or pathophysiologic significance of the "treatable trait" high blood eosinophil count in COPD is the same as for asthma remains controversial. We sought to determine the relationship between the blood eosinophil count, clinical characteristics and gene expression from bronchial brushings in COPD and asthma.MethodsSubjects were recruited into a COPD (emphysema versus airway disease [EvA]) or asthma cohort (Unbiased BIOmarkers in PREDiction of respiratory disease outcomes, U-BIOPRED). We determined gene expression using RNAseq in EvA (n = 283) and Affymetrix microarrays in U-BIOPRED (n = 85). We ran linear regression analysis of the bronchial brushings transcriptional signal versus blood eosinophil counts as well as differential expression using a blood eosinophil > 200 cells/μL as a cut-off. The false discovery rate was controlled at 1% (with continuous values) and 5% (with dichotomized values).ResultsThere were no differences in age, gender, lung function, exercise capacity and quantitative computed tomography between eosinophilic versus noneosinophilic COPD cases. Total serum IgE was increased in eosinophilic asthma and COPD. In EvA, there were 12 genes with a statistically significant positive association with the linear blood eosinophil count, whereas in U-BIOPRED, 1197 genes showed significant associations (266 positive and 931 negative). The transcriptome showed little overlap between genes and pathways associated with blood eosinophil counts in asthma versus COPD. Only CST1 was common to eosinophilic asthma and COPD and was replicated in independent cohorts.ConclusionDespite shared "treatable traits" between asthma and COPD, the molecular mechanisms underlying these clinical entities are predominately different.

More information Original publication

DOI

10.1111/all.14016

Type

Journal article

Publication Date

2020-02-01T00:00:00+00:00

Volume

75

Pages

370 - 380

Total pages

10

Addresses

I, n, s, t, i, t, u, t, e, , f, o, r, , L, u, n, g, , H, e, a, l, t, h, ,, , L, e, i, c, e, s, t, e, r, , N, I, H, R, , B, i, o, m, e, d, i, c, a, l, , R, e, s, e, a, r, c, h, , C, e, n, t, r, e, ,, , U, n, i, v, e, r, s, i, t, y, , o, f, , L, e, i, c, e, s, t, e, r, ,, , L, e, i, c, e, s, t, e, r, ,, , U, K, .

Keywords

U-BIOPRED and the EvA study teams, Respiratory Mucosa, Eosinophils, Th2 Cells, Humans, Asthma, Pulmonary Disease, Chronic Obstructive, Immunoglobulin E, Leukocyte Count, Prospective Studies, Aged, Middle Aged, Female, Male, Transcriptome, Biomarkers, RNA-Seq